Philogen Provides Corporate Update
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trials Use of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical trials Early evidence of potent activity of Fibromun in combination with Standard of Care in last line patients with Glioblastoma and Soft